艾比特斯是由美国英克隆(Imclone)公司开发的一种免疫球蛋白单克隆抗体,通过靶向作用于癌细胞表面的抑制表皮生长因子受体(EGFR),减少癌细胞进入正常组织的几率,控制...
基于460个网页-相关网页
现在，西妥昔单抗毕竟还是获批了，英克隆的股价也已反弹。
Now, Erbitux has been approved after all, and ImClone's stock has rebounded.
基因技术公司和从英克隆公司的老板都随随便便地就拒绝了收购的出价。
The bosses of both Genentech and ImClone have unceremoniously rejected the offers made by their partners.
英克隆将提留西妥昔单抗在美收入的39%，而百时美施贵宝将获得其余部分。
ImClone will keep 39 per cent of US revenues from Erbitux, with Bristol-Myers Squibb taking the rest.
应用推荐